Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HER2Bi-Armed Activated T Cells in Ovarian Cancer
NCT02470559Phase 1Withdrawn
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jun 2015
- Primary completion
- Feb 2017
- Modality
- Bispecific Antibodies, Cell Therapies
01
Overview
Phase 1, open-label, single-arm trial of HER2Bi-armed activated T cells in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC), sponsored by Barbara Ann Karmanos Cancer Institute. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Toxicity Profile at 2 years. Planned start Jun 2015; status: withdrawn.
02
Drugs
HER2Bi-armed activated T cells
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT02470559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02470559.